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Sixty patients who had recurrent episodes of symptomatic
atrial fibrillation or flutter, or both, and who had failed one
to five prior drug trials were treated with open label oral
propafeaone hydrochloride . On a mean maximal tolerated
done of 795 t 180 mg/day, actuarial estimates of the
percent of individuals tree of rcsrrene s of sympta omit
atrid fibrglatlonlflatter during propafeeorte treatment
were: I month, 54%; 3 months, 44% and 6 remains, 40% .
No individual baseline characteristic achieved statistical
Atrial fibrillation, an extremely common
rsr
_i
nc
rhythm
disturbance, is estimated to occur in 0 .4% of the general
adult population and in 2 to 4% of adults >60 years of age
(1,2) . Although control of the ventricular rate in atria)
fibrillation can usually be achieved by pharmacologic mea-
sures and sinus rhythm restored at least temporarily in the
majority of patients with direct current cardioversion, long-
term suppression of recurrences of atria) fibrillation is a more
difficult task (3). Quinidine, procainamide and disopyramide
are the antiarrhythmic agents usually prescribed to suppress
recurrences of atrial fibrillation, but to date, no large scale
randomized clinical trials have been performed to examine
rigorously their efficacy for this purpose. Furthermore, these
antiarrhythmic drugs are often poorly tolerated during long-
term treatment, necessitating discontinuation of therapy
regardless of drug efficacy .
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significance as a correlate of poor response to propafenone .
Drug-rotated adverse reactions were reported in 22% of
patients but were severe euorgl1 to require termination of
propafeame in only 5% .
Thus, oral penpahaone w
a uafd and well tolerated
drug for beg-teran smote of symptomatic recurrences
of aerial RbriiWloulflantter despite a history of unrespm-
aveeess to prior anderrhythodc drug treatment .
(J Am Cog Cmrefinf 19M,131 100$41)
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The class IC antianhythmic agent propafe,norle hydro-
chloride has an electrephysiologic profile that suggests it
might be a potent alttifibrillatory drug
(4) . Preliminary re-
ports (5) indicate that it is associated with a relatively low
incidence of intolerable side effects
. The present study was
undertaken to -examine the efficacy and tolerability of long-
term oral treatment with propafenone for suppression of
symptomatic, recurrent and refractory atriat F ;Jrillation.
Methods
Study pationl: e1Mry criteria. Between March 1985 and
June 1987, patients >18 years of age referred from the
medical services of the Brigham and Women's Hospital,
Beth Israel Hospital and Children's Hospital Medical Center
in Boston were screened for inclusion in the protocol . Entry
criteria included the following : 1) Electrocardiographic
(ECG) documentation of a history of atrial fibrillation, atrial
flutter or an ECG hybrid of the two rhythms (atrial flutter!
fibrillation); 2) Past medical records indicating at bast one
successful previous trial of suppressive antiarrhythmic ther-
apy with one or more of the following drugs : quinidine,
procainamide or disopyramide. Therapy was considered
unsuccessful if a) atrial fibrillation or atrial flutter, or both,
recurred despite therapeutic doses ; or b) side effects neces-
sitating termination of the drug occurred regardless of the
adequacy of arrhythmia suppression, or both . 3) Historical
evidence that occurrence of atria) fibrillatiodflutter was
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reliably associated with symptoms easily recognized by the
patient, such as palpitation, light-headedness, syncope or
paroxysmal dyspnea .
Patients were excluded if they had one or more of the
following: I) cardiogenic shock, 2) acute myocardial infarc-
tion within the preceding 7 days, or 3) transient atria)
fibrillation/flutter resulting from an unresolved acute or
subacute provocative disturbance such as pulmonary embo-
lism, pneumonia or uncontrolled congestive heart failure .
Individuals with pericarditis were considered for inclusion
only if they had a chronic relapsing form of the disease, as
manifested by 4) overt acutely deteriorating hepatic or renal
function, or 5) treatment with oral amiodarone within the
preceding 12 months if they had received maintenance
amiodarone therapy for act month .
Protocol Design
Drug treatment schedule. The trial consisted of three
phases that were related to propafenone dosing
: a loading
phase . a dose titration phase and a long-term maintenance
phase . All patients were hospitalized on an ECG telemetry
ward during the loading phase and initial dose titration phase
of 'the study. Patients were not hospitalized during the
long-term maintenance phase of the study . Before initial
loading with propafenone, all antiarrhythmic drugs were
discontinued . When clinically feasible, agents being used to
control the ventricular rate in atrial fibrillation/flutter (e.g .,
digitalis, beta-adrenergic blocking agents, verapamil and
diltiazem) were also discontinued in an attempt to minimize
any potentially confounding electrophysiologic effects
of
concurrently administered agents .
At the time of enrollment into the study, patients were
classified into one of two groups
based on the predominant
pattern their arrhythmia had exhibited in the month before
entry into the study
. One group comprised those patients
whose arrhythmia was characterized by recurrent, self-
terminating episodes, usually no more than 24 to 48 h in
duration, interspersed with long periods of sinus rhythm
;
this group was designated as having paroxysmal atrial fibril-
lation. The second group incirded individuals in whom atria)
fibrillation/flutter was the predominant and chronic rhythm,
sinus rhythm having been observed only transiently after
previous attempts at electrical or pharmacologic cardiover-
sion . This group was designated as having chronic atria)
fibrillation .
After informed consent was obtained, patients were
started on treatment with open label propafenone tablets
(Knoll Pharmaceutical Corp .)
. An oral loading dose of 300
mg was given followed by an initial maintenance dose of ISO
mg every 8 h (450 mg/day)
. During the ensuing dose titration
period patients received increasing maintenance doses that
ranged between 150 n
:g every 6 h (600 mg/day) to the trial
maximal dose of 300 mg every 8 h (900 mg/day)
. Dose
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titration occurred over several days to weeks, with increases
in dose being dictated by clinical response . For patients with
paroxysmal atrial fibrillation, each time the arrhythmia re-
curred the propafenone dose was increased as tolerated up
to the trial maximum . For patients with chronic atria)
fibrillation, the propafenone dose during the titration phase
was increased as tolerated to the trial maximum of 900 mg/
day. After steady state on the maximal tolerated dose was
achieved, direct current cardioversion was performed in
patients whose chronic atria) fibrillation did not convert
pharmacologically to normal sinus rhythm .
For all patients entered into the trial, the only indication
for a downward adjustment in the dose during the long-term
maintenance phase was the appearance
of drug-related side
effects . No attempt was made to determine the minimal
effective dose for suppression of arrhythmia recurrence.
Serum concentrations of propafenone and its two active
metabolites, 5-hydroxypropafenone and N-depropylpropafe-
none, were not routinely used to modify dosage schedules .
The dose reported for each patient, therefore, represents the
maximal tolerated propafenone dose established during the
long-term maintenance phase of the study .
Documentation of recurrence of arrhythmia . Patients and
referring physicians were required to document any recur .
rences of symptomatic atrial fibrillation/flutter once the dose
titration phase had been completed by recording a 12 lead
ECG, 24 h ambulatory ECG or rhythm strip obtained by
telemetry or telephone ECG transmitter . To maximize the
chance of documenting recurrences of arrhythmia and to
determine the interval that had elapsed between completion
of the titration phase of propafenone therapy and recurrence
of arrhythmia, all patients with a pattern of paroxysmal atria)
fibrillation were supplied with a telephone ECG transmitter
at the time of hospital discharge (6). To ensure that all such
patients had a transmitter available during the highest risk
period (i.e., the first few months of therapy) devices were
assigned as needed from subjects who had been free of
arrhythmia the longest (?3 to 6 months) . All patients were
seen by one of the study physicians or a specially trained
cardiovascular resear
c
h nurse, or both, every 3 months for
evaluation of cardiac rhythm and review of possible drug-
related side effects . More frequent visits were arranged as
needed whenever patients reported symptoms that sug-
gested recurrence of arrhythmia. Patients were encouraged
to utilize the telephone ECG system freely not only to
document arrhythmia recurrence but also to maintain con-
tact with study personnel and to ensure compliance with the
protocol.
Data collection. On each patient's entry into the study,
all relevant cardiac diagnoses were tabulated and the number
of prior antiarrhythmic drug trials was determined. Each
patient also had a baseline evaluation of hematologic, renal
and hepatic function, along with a chest roentgenogram and
12 lead ECG
. An eehocardiographic examination was per-
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formed to evaluate any underlying cardiac disease, measure
anteroposterior left atria) dimension and determine the left
ventricular ejection fraction .
For each patient, the number of months elapsed since the
original ECG-documented diagnosis of atria] fibrillation/
flutter was determined by review of all prior medical records
accessible to the study physicians . For patients in the
chronic atria) fibrillation group, pharmacologic conversion to
sinus rhythm from chronic atria) fibrillation during the dose
titration period was noted . In patients in this group who
required synchronized direct current cardioversion to re-
store sinus rhythm, an energy titration technique was uti-
lized to determine the minimal energy required to terminate
the arrhythmia. Recurrence of arrhythmia in the paroxysmal
and chronic aerial fibrillation groups was then tabulated
during the long-term maintenance phase of propafenone
therapy. Propafenone-related side effects were detected
from patient interviews and physical examinations . Special
note was made of the incidence of those side effects that led
to discontinuation of the drug .
Longitudinal follow-up and study termination . All pa-
tients were followed up as long as they received propafe-
none. Patients who lived at a distance from the hospital that
precluded frequent office visits were followed up by periodic
telephone contact and transtelephonic ECG transmissions
.
At the time of the first ECG-documented symptomatic
recurrence of atria] fibrillationtflutter during treatment with
the maximal tolerated dose of propafenone, or when intol-
erable side effects necessitated withdrawal of the drug,
propafenone therapy was considered to have failed and the
patient was offered alternative antiarrhythmic therapy .
Statistic analysis- Actuarial estimates of recurrence-
free intervals for all patients were calculated by the product
limit method of Kaplan and Meier (7,8) . The univariate
association of baseline characteristics and diagnoses with
freedom from recurrences was determined using a Cox
proportional hazards linear regression model (9) . Patients
who remained in normal sinus rhythm were censored if and
when they were withdrawn from treatment because of intol-
erable side effects. All statistical analyses were performed
using the Statistical Analysis System (10) .
Results
Clinical characteristics of study group (Table 1) . Sixty
patients (38 men and 22 women) were enrolleo in the trial.
Twenty-five patients (42%) were categorized as having
chronic atria) fibrillation, and 35 (58%) as having paroxysmal
atrial fibrillation . Only one patient had classical atrial flutter ;
all the others had either atrial fibrillation or lariat fibrillation/
flutter . A median of 30 months (range 0.3 to 576) had elapsed
since arrhythmia was first documented by ECU . A median of
two (range one to five) prior antiarrhythmic drug trials had
been unsuccessful
. In the group with paroxysmal atrial
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Tablet . Clinical Characteristics of Study Group
'Each patient could have more than one. Co.,tinuous variables are
preserved a t I SD escept as iadkaeed ranges are shown in
parentheses`CAD -coronue arterydisease :LA=left atrium :LVEF=left
servrklulcr ejection fraction : SSS = sick sinus syndrome .
fibrillation, the incidence rate of arrhythmic events per
patient-r-onth at 12 and 6 months and I month before
administration of propafenone was 9.6, 10.6 and 15.3 . re-
spectively. The cercent of patients who had been unsuccess-
fully treated in previous antiarrhythmic drug trials with each
of the three conventional agents was 90. 75 and 37%,
respectively, for quinidine, procainamide and disopyramide .
The scope of cardiac diagnoses was broad, encompassing all
of the common conditions usually noted in patients referred
for management of atrial fibrillation/flutter . During the
course of the trial, tie mean maximal tolerated dose of
propafenone for the group was 795 ± 182 mg/day. Nine
patients received a beta-adrenergic blocking agent, 17 re-
ceived digoxin and 9 received verapamil during the initial
phase of the follow-up period .
Efficacy
and Tolerability of Long-Term Oral
Propafenone
Initial restoration of sinus rhythm
. Of the 25 patients
with chronic atria) fibrillation, none exhibited pitarntacoiogie
conversion to sinus rhythm during the dose-titration phase of
propafenone therapy . Twenty-one of these 25 patients un-
derwent successful direct current cardioversion to sinus
rhythm at a mean energy level of 188 m 94 W-s (range 30 to
400)
. The four other patients with chronic atrial fibrillation
did not require cardioversion . In these four oral propafenone
Patients Ino.l 6a Imen, Ix: women, 221
A,c NO 62 1109 1 . Sit
Morvhc since diagnosis of arrhythmia,
median
30 (0
.3 to
576)
Previous amlarrhythmic drag trials,
median
211 to 5)
LA arlcropnsterior dimension (cell 4.6 _ 1 .0 (2 .9 to 7.4)
LVEF PIi i
55 t 15 (13 to
78)
Roots I I month before entry )
Chronic 25142`7)
Paeoxysmai 35(58%,)
Cardiac diagnosis'
Voloolar seen donate 15 (25%)
Left venoicalar systolic 10133:5)
dysfunction
Pulmonary disease 1 (L6%)
Hyperthyroidism
10 .6171)
Hypertension 17 (22015)
,. .
r
tlype)impho r ,
4T
y 31%t)
Fericardialdiseam 111.613)
Other
ISSS. CAD with infarction)
16 (271, .
No other cardiac diagnosis 9(15251
identified
1
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Figure l . Actuarial estimate of percent of patients free from elec-
trocardiographically documented symptomatic recurrences of atria)
fibrillation/flutter for the entire study group of 60 patients . The
estimates after 6 months (dashed line) are limited by the small
number of patients In = 151 who have been followed up beyond that
time .
loading was performed after restoration of sinus rhythm by
other medical therapy that had to be discontinued because of
intolerable side effects .
Actuarial estimates of freedom from symptomatic arrhyth-
mia recurrences (Fig. 1) . The percent of individuals free of
symptomatic arrhythmia recurrences declined most mark-
edly during the first 3 months of propafenone treatment and
tended to level off thereafter . By 6 months, 40 of patients
remained free of such recurrences ; the level of clinical
response appeared to remain relatively constant beyond that
point. Because only 15 patients free of recurrent symptom-
atic arrhythmia have been followed up beyond 6 months,
estimates of propafenone efficacy beyond that point have
wide confidence intervals .
Side effects
.
Drug-related adverse reactions were re-
ported by 13 (22%) of the 60 patients
. These consisted of
gastrointestinal intolerance in 4 (6
.6%), metallic taste in 6
(I(1%) and central nervous system complaints (dizziness,
headache, blurred vision) in 6 (10%)
. In three individuals
(5 .0%) propafenone side effects were sufficiently intolerable
to require discontinuation of the drug. For the group as a
whole, no significant drug-related alterations in hematologic,
renal or hepatic function occurred during the course of the
trial and no atrial or ventricular proarrhythmic events were
detected
. QRS duration during propafenone therapy (89
1 .7 ms) did not differ from baseline QRS duration (90 ± 1
.6
Its) (p = 0.56) .
Correlates of poor response to propafenone (Table 2) .
Although no individual characteristic was a statistically
significant correlate of failure to respond to propafenone,
trends were noted for male patients, a pattern of chronic
atria) fibrillation, an increasing number of prior unsuccessful
antiarrhythmic drug trials and increasing left atrial antero-
JACC Vol. 12, No 4
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Table 2 . Correlates of Recurrent Arrhythmia Despite Propafenone
Therapy in 60 Patients
95%
Incidence Rate
Confidence
Variable Ratio- Intervals
1 .81
0
.85In3.87
1
.62
0 .83103.16
Male gender
Chronic artist fibrillation
pane .
Number of previous 1 .333 0.98to1.82
unsuccessful drug
trials
Left atria] anleropastcriar 1
.20t
0.871. La;
dimension
Hncidenc rate of recurrent arrhythmia in patients with risk factor vs .
incidence late of recurrent arrhythmia in patients without risk factor
: tfor
each additional prior unsuccessful drug trial ; $for each additional I can of left
.riot size.
posterior dimension . Other variables were not significantly
correlated with recurrence rate (all p > 0 .2 in univariate Cox
regression models). These included age; number of months
since original diagnosis of atrial fibrillation/flutter ; all cardiac
diagnoses ; left ventricular ejection fraction ; body surface
area; concomitant therapy with verapamil, digoxin or a
beta-adrenergic blocking agent and arrhythmia frequency at
12 months, 6 months and I month before trial entry in the
paroxysmal atria) fibrillation group .
Discussion
Recent epidemiologic studies (1I) suggest that chronic
atrial fibrillation is associated with an increased risk of
mortality from cardiovascular disease as well as mortality
from noncardiovascular causes . Both chronic, sustained
atrial fibrillation and paroxysmal atrial fibrillation appear to
be risk factors for embolic cerebrovascular events, even
when they occur in the absence of underlying rheumatic
heart disease (12-17). Although sinus rhythm can frequently
be restored in patients with atrial fibrillation or flutter by
means of synchronized direct current cardioversion, the
recurrence rate of arrhythmia is high when such patients do
not receive maintenance treatment with antiarrhythmic
drugs (3,18-28) . Only 30 to 50% of untreated individuals
remain in sinus rhythm 3 to 6 months after conversion from
atria) fibrillation, with probably <2001o of such individuals
remaining in sinus rhythm by the end of I year (18-29).
Previous trials of suppressive antiarrhythmic therapy . It
has been suggested
that . in addition to underlying cardiac
diagnosis, two factors that help predict whether or not a
patient will maintain sinus rhythm during treatment are
chronicity of the arrhythmia before treatment and left atria)
size (3,25,30-33). After the original observations by de
Senac in 1749 (34) and subsequent studies in Europe and the
United States during the early part of this century (18,35-
SACC vw . 12, No. 4
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39), quinidine emerged as the drug of choice for suppression
of recurrences of atria( fibrillation or atria) flutter . However,
pooled data from uncontrolled studies and controlled trials
with small sample sizes suggest that treatment with quinidine
after restoration of sinus rhythm is only modestly effective
because sinus rhythm is maintained in only 50 to 60% of such
patients at the end of 6 months and in fewer still after longer
periods of time (18). : ew reported data are available regard-
ing the efficacy of quinidine in maintaining sinus rhythm after
administration for >1 year . Furthermore, quinidine prepara-
tions are poorly tolerated by many patients and frequently
must be discontinued because of intolerable side effects,
regardless of efficacy ( 40-42) . The limited number of re-
ported trials (30,43) does not suggest that other available
drugs like procainamide or disopyramide offer any greater
degree of efficacy Or are significantly better tolerated when
administered over a long-term period to suppress recur-
rences of atrial fibrillation/flutter .
Critique of current study. The present study was de-
signed to evaluate the ability of long-term treatment with
oral propafenone to preserve sinus rhythm in patients with
refractory symptomatic atrial fibrillation and atria) flutter.
Recent data suggest that both of these rhythm disturbances
may be due to the same underlying electrophysiologic mech-
anism, namely, reentry in atria) muscle (44,45) . Electrocar-
diographic patterns in individual patients frequently convert
spontaneously between atria] fibrillation and atrial flutter, or
may appear as a hybrid of both rhythms. Furthermore,
previous studies (46,47) have demonstrated that both
rhythms may coexist in different regions of the atria at the
same time . For these reasons no attempt was made in the
present study to differentiate between the two rhythms .
These results suggest that long-term oral propafenone
therapy is useful for suppression of symptomatic recur-
rences of atrial fibrillationiflutter despite a history of unre-
sporsivoness to prior antiarrhythmic drug treatment .
Because of study design, however, brief periods of asymp-
tomatic arrhythmia recurrences may have gone undetected
during propafenone therapy.
Although our need to reassign telephone transmitters for
some patients who remained asymptomatic up to 3 to 6
months could theoretically have resulted in failure to detect
subsequent symptomatic recurrences of paroxysmal atria]
fibrillation, we do not believe this is likely to have introduced
substantial bias. First, only 3 (8%) of 36 patients in the
combined paroxysmal and long-term groups had asymptom-
atic recurrences of atrial fibrillation by 6 months that were
detected only because of routine telephone transmissions .
Second, all individuals who developed symptomatic palpita-
tion but did not have a telephone transmitter available
beyond 6 months had either a 12 lead ECG or a 24 h
ambulatory ECG at the time of symptoms to document
whether they had atrial fibrillation or sinus rhythm . Thus, we
believe it is unlikely that we failed to diagnose a substantial
ANTMAN ET AL.
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number of potentially diagnosable cases of paroxysmal atrial
fibrillation .
Univariaie analysis of covariares showed trends suggest.
ing that maintenance of sinus rhythm and prevention of atria)
fibrillation/flutter by propafenone is more likely to occur in
patients whose arrhythmia was paroxysmal More therapy
and in those whose left atrium was smaller . It is possible that
with a larger sample size and longer follow-up these obser-
vations would achieve statistical significance. As in numer-
ous previous trials of suppressive antiarrhythmic therapy,
the present study demonstrates that the majority of individ-
uals who develop recurrences of aerial fibrillation/flutter
during drug treatment do so within the first I to 3 months
(18).
Our findings are even more striking when one considers
the nature of the patients who were enrolled in this study and
the data should he viewed in comparison with data from
other trials that tested the efficacy of various quinidine
preparations for suppression of recurrent arrhythrtia (19-
24,26,37-39) . We did not exclude patients with a long
duration of atria) fibrillation or those with left atrial enlarge-
ment. The arrhythmia of the patients studied had failed to be
adequately controlled during prior treatment with one or
more antiarrhythmic agents . Furthermore, rigorous efforts
including use of the relatively new technique of telephone
ECG arrhythmia surveillance (6), were made to document
the timing of all recurrences of arrhythmia . Thus, compared
with previous trials, the present study contained biases
toward individuals who would be expected to have arrhyth-
mia that was particularly refractory to treatment and detec-
tion of al . ;,ythmia recurrences may have been more reliable .
Comparison with
other prepefewme
trials. Previous
studies (48-54) have also suggested that long-term propafe-
none therapy may be useful for the management of atrial
fibrillation/flutter, even when the arrhythmia has been re-
fractory to treatment with other agents . These reports dif-
fered from the current study in that fewer patients with atria)
fibrillation/flutter were studied, the duration of follow-up
was shorter and, in some reports, patients with less refrac-
tory arrhythmia were enrolled . Furthermore, previous stud-
ies usually did not distinguish between patients with parox-
ysmal atria] fibrillation/flutter and those whose arrhythmia
was chronic and sustained . One observation common to the
present study as well as all previous reports (5) is the low
incidence of serious adverse reactions associated with long-
term oral propafenone therapy . Among patients reported in
the present study, intolerable side effects that led to discon-
tinuation of propafenone occurred in only 5% of the group
.
Clinical Implications. In view of the efficacy and the low
incidence of side effects noted during this and other studies,
long-term propafenone therapy appears to
be an important
new antiarrhythmic option that should be offered to patients
with atrial fibrillation/flutter unresponsive to prior anti-
arrhythmic regimens. One question still to be resolved is
1 01 0
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whether propafenone should be considered as initial therapy
in patients with atrial fibrillation/flutter rather than reserved
for use only in patients with refractory arrhythmia
. This
question can only be answered with a large scale randomized
clinical trial comparing long-term oral propafenone therapy
versus long-term oral therapy with agents like quinidine and
procainamide, which currently are used as drugs
of
first
choice .
We acknowledge the invaluable assistance of Pamela Alvarez, Victoria
Gescbwind. Harry Nasson and Maria Bosak . RN in the long-term ECG
monitoring of the patients in this study . Mary Gillen provided expert edilorial
assistance
.
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